OUR VISION

Antony Koblish is a medical device entrepreneur with 25 years of experience in health care. Prior to founding TELA Bio, Mr. Koblish was President and Chief Executive Officer of Orthovita, Inc., a publicly traded orthobiologics and biosurgery medical device company. During his tenure as Chief Executive Officer of Orthovita from 2002 to 2011, Mr. Koblish created significant company value, growing valuation from $30M to a $316M exit sale to Stryker Corporation in 2011. He is a skilled leader with a proven track record in driving sales growth, building a robust product pipeline, establishing world-class commercial operations, and instilling clinical and manufacturing quality. Mr. Koblish is also a co-founder and currently serves as Chairman of the Board of Onkos Surgical, Inc., a surgical oncology company, and is an operating partner with 1315 Capital, a private investment firm that provides expansion and growth capital to commercial-stage specialty pharmaceutical, medical technology, and health care services companies. Mr. Koblish earned a Master of Science in Engineering degree in Mechanical Engineering and Applied Mechanics from the University of Pennsylvania and holds a Bachelor of Science degree in Mechanical Engineering from Worcester Polytechnic Institute.

Skott Greenhalgh has 20 years of industrial experience, 18 years in the development and manufacturing of medical devices, and two years of teaching and research at North Carolina State University and Philadelphia University. Dr. Greenhalgh has a strong understanding of the medical device clinical and regulatory pathways, and he has lead teams of highly skilled research and development personnel focused on cardiovascular, general surgical, and orthopedic medical device implants. Dr. Greenhalgh has developed multiple hybrid biologic implant devices, with numerous patents issued. He has directed research and development activities for multiple strategic partnerships and co-development programs, including minimally invasive cardiovascular, spinal, surgical, and neurologic implants with multiple start-ups and Fortune 500 medical device companies, and has raised more than $19M in outside capital to fund these efforts. He has licensed 14 medical implant technologies, 10 of which he was initial inventor/creator, and sold one company. Dr. Greenhalgh received his PhD in Fiber and Polymer Science and his master's degree in Textile Engineering from North Carolina State University. His Bachelor of Science degree in Mechanical Engineering is from Drexel University.

Paul Talmo possesses over 20 years of experience commercializing technologies within the medical device and service industries including medical devices, implantable materials, as well as imaging and diagnostic technologies and services. Mr. Talmo spent 16 years at LifeCell Corporation and was an impetus behind the transformation of a burn focused company into a soft tissue reconstruction company. Mr. Talmo was responsible for first introducing biologic materials to the urogynecology market, for urinary incontinence and pelvic floor reconstruction, as well as the general surgery market, for hernia repair. Mr. Talmo also worked closely with surgeons to develop the various techniques and protocols for implant-based reconstruction with the first biologic material used in breast reconstruction, eventually commercializing the material and new techniques in the early 2000s. Mr. Talmo applies his years of clinical and commercial experience with innovative and strategic thinking to create unique disruptive business models.

Peter Murphy has more than 20 years of commercial sales and marketing experience at leading medical device and pharmaceutical companies. Prior to joining TELA Bio, Mr. Murphy held the position of Vice President of Sales at Pacira Pharmaceuticals, Inc. where he led the domestic sales team to significant year-over-year growth with their core drug therapy, EXPAREL®. In addition, Mr. Murphy spent over a decade in the orthopedic space where he held various sales management roles within Stryker Corporation and Medtronic Spine and Biologics. During this time, Mr. Murphy successfully supported the commercialization and market growth of several advanced orthopedic biomaterials including the recombinant human growth factors, rhPDGF and rhBMP. Mr. Murphy graduated with a Bachelor of Arts degree in Business from Gettysburg College.

Antony Koblish is a medical device entrepreneur with 25 years of experience in health care. Prior to founding TELA Bio, Mr. Koblish was President and Chief Executive Officer of Orthovita, Inc., a publicly traded orthobiologics and biosurgery medical device company. During his tenure as Chief Executive Officer of Orthovita from 2002 to 2011, Mr. Koblish created significant company value, growing valuation from $30M to a $316M exit sale to Stryker Corporation in 2011. He is a skilled leader with a proven track record in driving sales growth, building a robust product pipeline, establishing world-class commercial operations, and instilling clinical and manufacturing quality. Mr. Koblish is also a co-founder and currently serves as Chairman of the Board of Onkos Surgical, Inc., a surgical oncology company, and is an operating partner with 1315 Capital, a private investment firm that provides expansion and growth capital to commercial-stage specialty pharmaceutical, medical technology, and health care services companies. Mr. Koblish earned a Master of Science in Engineering degree in Mechanical Engineering and Applied Mechanics from the University of Pennsylvania and holds a Bachelor of Science degree in Mechanical Engineering from Worcester Polytechnic Institute.

Doug Evans has served as the President and Chief Executive Officer of Lungpacer Medical Inc., a medical device company, since January 2014. Prior to joining Lungpacer, Mr. Evans served as the Chief Operating Officer and a member of the board of directors of Kensey Nash Corporation, a medical device company, from March 1995 to June 2013. Mr. Evans currently serves on the board of directors of Intact Vascular, a medical device company. Mr. Evans holds a Master of Science degree in Electrical Engineering and Photonics from the University of Pennsylvania, a M.B.A. from Pennsylvania State University Great Valley School of Graduate Professional studies and a Bachelor's of Science in Engineering Sciences from the Pennsylvania State University. Mr. Evans is the co-founder of the Cure4Cam Childhood Cancer Foundation, which seeks to raise community awareness concerning, and supports the development of, new and more humane therapies for childhood cancer.

Federica O'Brien has over 25 years of executive financial and operational leadership in biopharmaceutical, medical device and technology companies. Ms. O'Brien has held a variety of senior roles, including Chief Financial Officer, Chief Operating Officer, Controller and Director of Financial Reporting, at both private and public companies that range from early through commercial stage. Currently Ms. O'Brien is President of CFO'Brien Consulting, LLC for which she provides C-Suite level strategic and financial consulting; her prior experience includes leadership roles at Complexa Inc., Cerecor Inc., Cervilenz Inc., Cardiokine Inc., Barrier Therapeutics, Inc. and Infonautics, Inc. Before specializing in life sciences and technology, Ms. O'Brien spent over a decade in professional service accounting firms, most recently at PricewaterhouseCoopers, where she was focused on high growth companies in multiple industries. She received her Bachelor of Arts degree in accounting from Rutgers University and is a Certified Public Accountant - Inactive.

Mr. Nosenzo has served as the Chief Commercial Officer of Bioventus Inc., a global leader in innovations for active healing, since February 2017. Before joining Bioventus, Mr. Nosenzo spent six years at Beckman Coulter serving as its Senior Vice President, Global Customer Operations. Previously, Mr. Nosenzo spent six years with Siemens serving as Vice President of Sales, Medical Testing Systems before being promoted to Senior Vice President, General Manager - Americas, and later as Senior Vice President, Customer Relations Management. Mr. Nosenzo also spent time at Quest Diagnostics serving as Vice President, Marketing and Sales. Mr. Nosenzo began his long career in healthcare with Bayer Healthcare, dedicating 15 years to their pharmaceutical division in various sales roles, including Vice President of Sales, Generic Product Division and later, Vice President of Marketing and Sales, Specialty Products of the Schein Pharmaceutical Division. Mr. Nosenzo received an MBA from Adelphi University in marketing and management and holds a Bachelor of Science from St. John's University in pharmacy.

Kurt Azarbarzin is President and Chief Executive Officer of Verb Surgical, Inc. and a member of the board of directors. He brings over 30 years of medical device industry and surgery market experience to the company. In his most recent role, he was Chief Technology Officer at ConMed Corporation, a global, publically-traded medical company specializing in surgical and patient monitoring technology. Prior to ConMed, Mr. Azarbarzin was the founder and Chief Executive Officer of SurgiQuest, Inc., a venture-backed medical device company that developed and commercialized innovative technologies for minimally invasive and robotic surgery, including the AirSeal® platform, and was later successfully acquired by ConMed. Prior to SurgiQuest, Mr. Azarbarzin held numerous Research and Development leadership positions at Covidien (now part of Medtronic). He currently serves as Chairman of the Board of Directors at Standard Bariatrics, Inc and is a member of the Executive Board at the Center for Biomedical Innovation and Technology at Yale University. Mr. Azarbarzin earned a Bachelor of Science from the University of Bridgeport and completed advanced graduate studies in mechanical design at Bridgeport Engineering Institute and manufacturing engineering at Bradley University.

Lisa Colleran has been the principal of LNC Advisors, LLC, a strategic consulting firm that specializes in assisting biotech, pharmaceutical, and medical device companies since February 2014. From October 2018 to September 2019, Ms. Colleran served as the Chief Executive Officer of Vivex Biomedical, Inc. Prior to founding LNC Advisors, Ms. Colleran served as chief executive officer of LifeCell Corporation and a board member for Centaur Guerney L.P. (a holding company of LifeCell Corporation) from January 2012 to April 2013. Ms. Colleran also served as the global president of LifeCell Corporation from May 2008 to January 2012. Prior to assuming the role of global president, Ms. Colleran served as LifeCell's vice president of marketing and business development from December 2002 until July 2004 and as senior vice president of commercial operations from July 2004 until May 2008. Prior to joining LifeCell, Ms. Colleran served as vice president and general manager of Renal Pharmaceuticals for Baxter Healthcare Corporation from 2000 to 2002 and served in various other sales and marketing positions at Baxter, from 1983 to 2000. Ms. Colleran currently serves on the board of directors for Establishment Labs, an innovative breast implant company, Ariste Medical, a medical device company and Rockwell Medical, a specialty pharmaceutical company focused on renal failure. Ms. Colleran holds an M.B.A. from Loyola University of Chicago and a B.S.N. degree from Molloy College.

Vince Burgess is President and Chief Executive Officer of Acutus Medical, Inc., an emerging medical device company in the cardiac electrophysiology field. Previously, Mr. Burgess was a Venture Partner with OrbiMed Advisors from 2010 to 2020. Mr. Burgess has more than 30 years of experience in health care operations, marketing, business development, and venture capital. Mr. Burgess was a crucial member of the founding executive team at Volcano Corporation, where he served as President of Advanced Imaging Systems. He also led marketing and business development at Volcano from 2002 to 2010 and was a key architect of the company's product, marketing, and mergers and acquisitions strategies. During his tenure, Volcano grew from a start-up to a global company with more than 1,000 employees and a market cap of more than $1.2 billion. Mr. Burgess previously served as a partner of Sorrento Ventures and has operational and board experience in the surgical tool, ophthalmology, and health care IT fields. He earned his Master of Business Administration from the University of California, Los Angeles, and his Bachelor of Science degree in Business Administration from the University of Southern California.